Srinivasan Dasarathy
Overview
Explore the profile of Srinivasan Dasarathy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
199
Citations
11957
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sengupta S, Anand A, Yang Q, Reagan M, Husted M, Minnick A, et al.
Hepatol Commun
. 2025 Feb;
9(2).
PMID: 39927894
Background: We analyzed early outcomes regarding the impact of our integrated alcohol-associated liver disease (ALD) clinic on patients with ALD and alcohol use. Methods: We conducted a retrospective study of...
2.
Aminian A, Aljabri A, Wang S, Bena J, Allende D, Rosen H, et al.
Nat Med
. 2025 Jan;
PMID: 39870816
No therapy has been shown to reduce the risk of major adverse liver outcomes (MALO) in patients with cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH). The Surgical Procedures Eliminate Compensated...
3.
Bosoi C, Kumar A, Oliveira M, Welch N, Clement M, Tremblay M, et al.
Metab Brain Dis
. 2025 Jan;
40(1):110.
PMID: 39847228
Sarcopenia and hepatic encephalopathy (HE) are complications of chronic liver disease (CLD), which negatively impact clinical outcomes. Hyperammonemia is considered to be the central component in the pathogenesis of HE,...
4.
Le P, Tatar M, Dasarathy S, Alkhouri N, Herman W, Taksler G, et al.
JAMA Netw Open
. 2025 Jan;
8(1):e2454707.
PMID: 39821400
Importance: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease and is projected to become the leading indication for liver transplant (LT) in the...
5.
Flanary J, King E, Baimaji F, Strauss A, Welch N, Bellar A, et al.
Gastro Hep Adv
. 2025 Jan;
4(1):100542.
PMID: 39802488
No abstract available.
6.
Wu J, Huang E, McMullen M, Singh V, Mrdjen M, Bellar A, et al.
Hepatol Commun
. 2024 Dec;
8(12.
PMID: 39621302
Background: Dichloroacetate (DCA), a pan-pyruvate dehydrogenase kinase inhibitor, ameliorates multiple pathological conditions and tissue injury and shows strong potential for clinical applications. Here, we investigated the preventive effects of DCA...
7.
Witkiewitz K, Mellinger J, Lee B, Dasarathy S, Nagy L, Mitchell M
Nat Rev Gastroenterol Hepatol
. 2024 Oct;
21(12):886.
PMID: 39402385
No abstract available.
8.
Kim M, Rouphael C, Wehbe S, Yoon J, Wisnivesky J, McMichael J, et al.
Gastro Hep Adv
. 2024 Sep;
3(7):910-916.
PMID: 39286619
Background And Aims: Gastric cancer (GC) is a leading cause of cancer incidence and mortality globally. Population screening is limited by the low incidence and prevalence of GC in the...
9.
Overstreet A, Burge M, Bellar A, McMullen M, Czarnecki D, Huang E, et al.
medRxiv
. 2024 Sep;
PMID: 39281760
Background And Aims: Alcohol-associated hepatitis (AH) is the most life-threatening form of alcohol-associated liver disease (ALD). AH is characterized by severe inflammation attributed to increased levels of ethanol, microbes or...
10.
Yang X, Bhowmick K, Rao S, Xiang X, Ohshiro K, Amdur R, et al.
Cell Rep
. 2024 Sep;
43(9):114676.
PMID: 39217614
Obesity and fatty liver diseases-metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH)-affect over one-third of the global population and are exacerbated in individuals with reduced functional aldehyde...